liraglutide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Glucagon-like Peptide (GLP) analogues 4164 204656-20-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • saxenda
  • liraglutide [rDNA origin]
  • liraglutide rDNA origin
  • liraglutide [rNDA origin] injection
  • liraglutide
  • NN2211
  • victoza
  • liraglutide recombinant
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
  • Molecular weight: 3751.26
  • Formula: C172H265N43O51
  • CLOGP:
  • LIPINSKI: None
  • HAC: 94
  • HDO: 54
  • TPSA: 1513.76
  • ALOGS:
  • ROTB: 130

Drug dosage:

DoseUnitRoute
40 U P
1.50 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance) 0.01 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 20, 2010 PMDA Novo Nordisk Pharma Ltd
June 30, 2009 EMA
Jan. 25, 2010 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 2227.64 15.19 776 19227 41838 50543283
Pancreatitis acute 640.62 15.19 268 19735 23544 50561577
Nausea 535.52 15.19 974 19029 704424 49880697
Pancreatic carcinoma 420.87 15.19 138 19865 6076 50579045
Diabetic ketoacidosis 350.00 15.19 161 19842 17711 50567410
Vomiting 298.27 15.19 597 19406 460161 50124960
Lipase increased 273.39 15.19 109 19894 8432 50576689
Blood glucose increased 271.50 15.19 225 19778 71099 50514022
Injection site urticaria 166.65 15.19 86 19917 12131 50572990
Eructation 157.88 15.19 70 19933 7051 50578070
Injection site rash 149.29 15.19 88 19915 16089 50569032
Weight decreased 146.13 15.19 290 19713 220955 50364166
Abdominal pain 143.42 15.19 299 19704 235929 50349192
Injection site erythema 133.20 15.19 156 19847 74780 50510341
Pancreatic carcinoma metastatic 128.80 15.19 43 19960 1999 50583122
Cholelithiasis 124.33 15.19 110 19893 37863 50547258
Glycosylated haemoglobin increased 114.72 15.19 64 19939 10542 50574579
Ketoacidosis 108.47 15.19 45 19958 3850 50581271
Injection site pruritus 103.27 15.19 102 19901 40309 50544812
Diarrhoea 102.63 15.19 481 19522 587995 49997126
Diabetes mellitus inadequate control 101.99 15.19 64 19939 13081 50572040
Blood glucose decreased 98.81 15.19 71 19932 18140 50566981
Hypoglycaemia 97.59 15.19 113 19890 53468 50531653
Medullary thyroid cancer 94.00 15.19 19 19984 107 50585014
Euglycaemic diabetic ketoacidosis 93.75 15.19 37 19966 2782 50582339
Amylase increased 91.09 15.19 44 19959 5386 50579735
Dehydration 87.72 15.19 189 19814 152260 50432861
Papillary thyroid cancer 83.33 15.19 31 19972 1984 50583137
Thyroid mass 79.99 15.19 35 19968 3413 50581708
Injection site reaction 69.34 15.19 92 19911 49940 50535181
Abdominal pain upper 67.16 15.19 175 19828 159134 50425987
Adenocarcinoma pancreas 66.36 15.19 22 19981 1000 50584121
Drug ineffective 65.62 15.19 142 19861 819191 49765930
Lactic acidosis 65.21 15.19 73 19930 33282 50551839
Thyroid neoplasm 57.56 15.19 28 19975 3479 50581642
Acute kidney injury 56.41 15.19 208 19795 227850 50357271
Thyroid cancer 55.83 15.19 29 19974 4140 50580981
Decreased appetite 55.46 15.19 190 19813 200733 50384388
Weight loss poor 48.52 15.19 17 19986 915 50584206
Impaired gastric emptying 47.30 15.19 34 19969 8684 50576437
Reversible cerebral vasoconstriction syndrome 44.31 15.19 20 19983 2099 50583022
Injection site haematoma 43.25 15.19 28 19975 6032 50579089
Drug dose titration not performed 42.58 15.19 13 19990 451 50584670
Constipation 42.26 15.19 165 19838 185543 50399578
Systemic lupus erythematosus 41.13 15.19 4 19999 140618 50444503
Pancreatic neoplasm 41.02 15.19 14 19989 696 50584425
Pyrexia 38.24 15.19 57 19946 380146 50204975
Joint swelling 36.86 15.19 26 19977 245260 50339861
Neutropenia 36.69 15.19 7 19996 147958 50437163
Glossodynia 34.56 15.19 3 20000 115566 50469555
Flatulence 34.54 15.19 50 19953 29408 50555713
Pancreatic enzymes increased 34.07 15.19 12 19991 656 50584465
Rheumatoid arthritis 33.83 15.19 19 19984 202531 50382590
Pain 32.99 15.19 118 19885 578785 50006336
Cholecystitis acute 32.47 15.19 25 19978 7081 50578040
Pancreatic mass 32.28 15.19 12 19991 766 50584355
Cholecystitis 31.73 15.19 33 19970 13838 50571283
Abdominal distension 31.60 15.19 81 19922 72822 50512299
Drug titration error 31.27 15.19 11 19992 599 50584522
Infusion related reaction 31.17 15.19 14 19989 169543 50415578
Arthropathy 29.08 15.19 13 19990 157893 50427228
Pancreatic cyst 29.02 15.19 13 19990 1340 50583781
Drug intolerance 27.08 15.19 28 19975 219076 50366045
Glycosylated haemoglobin decreased 25.89 15.19 9 19994 473 50584648
Treatment failure 25.87 15.19 11 19992 137626 50447495
Completed suicide 25.67 15.19 10 19993 131879 50453242
Hyperglycaemia 25.46 15.19 49 19954 36356 50548765
Therapeutic product effect decreased 25.37 15.19 11 19992 136039 50449082
Mental disability 24.94 15.19 6 19997 82 50585039
Goitre 24.93 15.19 19 19984 5301 50579820
Injection site pain 24.69 15.19 98 19905 110926 50474195
Death 24.55 15.19 58 19945 325321 50259800
Palpitations 23.97 15.19 87 19916 94419 50490702
Febrile neutropenia 23.41 15.19 5 19998 97662 50487459
Ductal adenocarcinoma of pancreas 23.14 15.19 6 19997 113 50585008
Haemoglobin decreased 22.61 15.19 11 19992 127205 50457916
Hypoglycaemic unconsciousness 22.35 15.19 9 19994 713 50584408
Genotype drug resistance test positive 21.90 15.19 7 19996 283 50584838
General physical health deterioration 21.50 15.19 15 19988 142419 50442702
Bile acid malabsorption 21.38 15.19 6 19997 154 50584967
Disease progression 20.86 15.19 6 19997 95860 50489261
Pancytopenia 20.77 15.19 4 19999 84026 50501095
Huerthle cell carcinoma 20.51 15.19 3 20000 0 50585121
Lack of satiety 20.51 15.19 3 20000 0 50585121
Toxicity to various agents 20.23 15.19 33 19970 212466 50372655
Pancreatitis necrotising 19.82 15.19 10 19993 1343 50583778
Blood calcitonin increased 19.30 15.19 4 19999 26 50585095
Blood glucose abnormal 19.21 15.19 18 19985 6654 50578467
Cholangiocarcinoma 19.12 15.19 9 19994 1039 50584082
Wound 19.02 15.19 9 19994 105785 50479336
Aerococcus urinae infection 18.43 15.19 3 20000 3 50585118
Pneumonia 18.40 15.19 82 19921 378319 50206802
Infection 18.26 15.19 25 19978 172929 50412192
Renal failure 18.25 15.19 87 19916 106546 50478575
Injection site nodule 18.03 15.19 13 19990 3335 50581786
White blood cell count decreased 18.01 15.19 12 19991 116710 50468411
Maternal exposure during pregnancy 18.00 15.19 22 19981 159756 50425365
Stomatitis 17.65 15.19 9 19994 101335 50483786
Dysgeusia 17.65 15.19 44 19959 38872 50546249
Pancreatic pseudocyst 17.57 15.19 7 19996 539 50584582
Increased appetite 17.54 15.19 19 19984 8342 50576779
Swelling 17.48 15.19 33 19970 200839 50384282
Anaemia 17.47 15.19 47 19956 252409 50332712
Malignant neoplasm progression 17.36 15.19 3 20000 68121 50517000
Hepatic steatosis 17.27 15.19 33 19970 24351 50560770
Glomerular filtration rate decreased 17.02 15.19 22 19981 11630 50573491
Gastritis 16.79 15.19 39 19964 32944 50552177
C-reactive protein increased 16.78 15.19 3 20000 66471 50518650
Injection site swelling 16.65 15.19 45 19958 41728 50543393
Thrombocytopenia 16.12 15.19 16 19987 127657 50457464
Anuria 16.06 15.19 21 19982 11223 50573898
Diabetic ketosis 15.99 15.19 5 19998 188 50584933
Bile duct stone 15.91 15.19 12 19991 3295 50581826
Somnambulism 15.57 15.19 14 19989 4910 50580211
Diabetic retinopathy 15.25 15.19 10 19993 2200 50582921
Metastases to liver 15.22 15.19 28 19975 20076 50565045

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 1783.97 15.46 654 13478 33860 29526535
Pancreatitis acute 527.09 15.46 249 13883 24136 29536259
Pancreatic carcinoma 432.89 15.46 153 13979 6997 29553398
Nausea 335.75 15.46 537 13595 288718 29271677
Diabetic ketoacidosis 286.43 15.46 144 13988 15929 29544466
Pancreatic carcinoma metastatic 222.52 15.46 73 14059 2648 29557747
Lipase increased 220.17 15.46 98 14034 8239 29552156
Blood glucose increased 186.50 15.46 182 13950 58802 29501593
Vomiting 161.42 15.46 329 13803 211931 29348464
Glycosylated haemoglobin increased 140.62 15.46 75 14057 9351 29551044
Diabetes mellitus inadequate control 122.96 15.46 75 14057 12059 29548336
Adenocarcinoma pancreas 112.74 15.46 36 14096 1195 29559200
Weight decreased 109.78 15.46 230 13902 150675 29409720
Abdominal pain 108.74 15.46 215 13917 135142 29425253
Cholelithiasis 98.04 15.46 77 14055 18595 29541800
Eructation 92.79 15.46 43 14089 3963 29556432
Lactic acidosis 82.01 15.46 86 14046 30161 29530234
Amylase increased 75.89 15.46 41 14091 5239 29555156
Diarrhoea 74.79 15.46 335 13797 332363 29228032
Injection site rash 69.53 15.46 34 14098 3530 29556865
Papillary thyroid cancer 65.80 15.46 20 14112 562 29559833
Toxicity to various agents 61.43 15.46 6 14126 173655 29386740
Ketoacidosis 60.07 15.46 31 14101 3608 29556787
Pancreatitis necrotising 60.04 15.46 27 14105 2320 29558075
Hypoglycaemia 59.80 15.46 93 14039 48253 29512142
Abdominal pain upper 58.93 15.46 105 14027 60888 29499507
Acute kidney injury 57.12 15.46 264 13868 265003 29295392
Thyroid cancer 52.62 15.46 21 14111 1341 29559054
Weight loss poor 50.43 15.46 12 14120 127 29560268
Medullary thyroid cancer 46.64 15.46 9 14123 30 29560365
Pancreatic carcinoma stage IV 45.08 15.46 13 14119 303 29560092
Injection site haematoma 43.70 15.46 19 14113 1506 29558889
Dyspepsia 43.01 15.46 62 14070 30063 29530332
Metastases to liver 41.94 15.46 39 14093 11817 29548578
Pancreatitis chronic 41.53 15.46 20 14112 2008 29558387
Thyroid mass 41.43 15.46 13 14119 407 29559988
Injection site erythema 40.17 15.46 41 14091 13915 29546480
Pancreatic neoplasm 39.71 15.46 15 14117 826 29559569
Gastrooesophageal reflux disease 39.49 15.46 61 14071 31435 29528960
Injection site pruritus 39.34 15.46 28 14104 5821 29554574
Dehydration 37.26 15.46 130 14002 114618 29445777
Pneumonia 33.50 15.46 64 14068 320108 29240287
Pancreatic pseudocyst 33.23 15.46 13 14119 787 29559608
Pancreatic mass 32.63 15.46 13 14119 826 29559569
Febrile neutropenia 32.46 15.46 7 14125 112233 29448162
Neutropenia 31.14 15.46 12 14120 131699 29428696
Abdominal discomfort 30.10 15.46 69 14063 47834 29512561
Cholecystectomy 29.88 15.46 17 14115 2400 29557995
Tonsillar ulcer 28.80 15.46 8 14124 162 29560233
Product use in unapproved indication 28.20 15.46 4 14128 86871 29473524
Cholangiocarcinoma 27.76 15.46 12 14120 938 29559457
Pyrexia 27.10 15.46 61 14071 287561 29272834
Decreased appetite 27.07 15.46 139 13993 145203 29415192
Blood glucose decreased 26.93 15.46 31 14101 12038 29548357
Death 26.55 15.46 80 14052 342004 29218391
Flatulence 26.08 15.46 37 14095 17672 29542723
Blood calcitonin increased 26.07 15.46 5 14127 16 29560379
Ketosis 25.37 15.46 9 14123 414 29559981
Thyroid neoplasm 25.31 15.46 9 14123 417 29559978
White blood cell count decreased 24.50 15.46 5 14127 83357 29477038
Thyroid adenoma 24.35 15.46 4 14128 3 29560392
Injection site reaction 23.73 15.46 28 14104 11160 29549235
Glycosylated haemoglobin decreased 23.27 15.46 8 14124 335 29560060
Diabetic metabolic decompensation 23.19 15.46 12 14120 1404 29558991
Drug ineffective 22.76 15.46 93 14039 363077 29197318
Pancreatic enzymes increased 22.54 15.46 9 14123 575 29559820
Platelet count decreased 22.41 15.46 11 14121 104661 29455734
Haemoglobin decreased 22.30 15.46 12 14120 108363 29452032
Injection site urticaria 21.84 15.46 12 14120 1584 29558811
Constipation 21.81 15.46 110 14022 114050 29446345
Thrombocytopenia 21.10 15.46 20 14112 134803 29425592
Pancreatic cyst 20.51 15.46 9 14123 729 29559666
Completed suicide 20.06 15.46 9 14123 90237 29470158
Acinar cell carcinoma of pancreas 19.94 15.46 3 14129 0 29560395
Skin wound 19.92 15.46 7 14125 313 29560082
Ludwig angina 19.76 15.46 6 14126 168 29560227
Extrasystoles 19.69 15.46 15 14117 3459 29556936
Ductal adenocarcinoma of pancreas 19.60 15.46 4 14128 19 29560376
Cholecystitis chronic 19.44 15.46 9 14123 827 29559568
Impaired gastric emptying 19.05 15.46 14 14118 3056 29557339
Euglycaemic diabetic ketoacidosis 18.64 15.46 13 14119 2617 29557778
Gallbladder enlargement 18.33 15.46 9 14123 942 29559453
Pancreatectomy 17.93 15.46 4 14128 31 29560364
Follicular thyroid cancer 17.86 15.46 3 14129 3 29560392
Anaemia 17.78 15.46 44 14088 200907 29359488
Confusional state 17.73 15.46 21 14111 127856 29432539
Supraventricular extrasystoles 17.33 15.46 13 14119 2928 29557467
Drug dose titration not performed 17.30 15.46 6 14126 258 29560137
Catheter site cellulitis 16.97 15.46 5 14127 126 29560269
Gallbladder disorder 16.86 15.46 17 14115 5683 29554712
Cholecystitis acute 15.98 15.46 16 14116 5303 29555092
Disease progression 15.53 15.46 10 14122 81906 29478489

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 2273.94 14.45 866 25201 58741 64413924
Pancreatitis acute 894.96 14.45 406 25661 42449 64430216
Nausea 617.94 14.45 1117 24950 784683 63687982
Diabetic ketoacidosis 557.78 14.45 262 25805 29583 64443082
Pancreatic carcinoma 550.96 14.45 193 25874 10180 64462485
Vomiting 358.29 14.45 725 25342 550392 63922273
Lipase increased 324.20 14.45 144 25923 14258 64458407
Blood glucose increased 320.02 14.45 286 25781 97787 64374878
Pancreatic carcinoma metastatic 232.77 14.45 77 25990 3401 64469264
Weight decreased 185.85 14.45 377 25690 285362 64187303
Eructation 184.93 14.45 85 25982 9106 64463559
Abdominal pain 183.20 14.45 395 25672 311980 64160685
Diabetes mellitus inadequate control 181.51 14.45 111 25956 21210 64451455
Glycosylated haemoglobin increased 177.64 14.45 99 25968 15920 64456745
Cholelithiasis 168.98 14.45 143 25924 45363 64427302
Ketoacidosis 168.60 14.45 73 25994 6790 64465875
Diarrhoea 158.88 14.45 643 25424 722061 63750604
Lactic acidosis 155.92 14.45 156 25911 61254 64411411
Adenocarcinoma pancreas 143.72 14.45 46 26021 1827 64470838
Hypoglycaemia 124.39 14.45 167 25900 89725 64382940
Acute kidney injury 121.76 14.45 428 25639 448812 64023853
Injection site erythema 115.95 14.45 143 25924 70657 64402008
Injection site urticaria 115.57 14.45 66 26001 11115 64461550
Papillary thyroid cancer 111.47 14.45 40 26027 2258 64470407
Euglycaemic diabetic ketoacidosis 108.72 14.45 50 26017 5360 64467305
Amylase increased 107.76 14.45 60 26007 9625 64463040
Injection site rash 94.82 14.45 66 26001 15676 64456989
Medullary thyroid cancer 90.40 14.45 19 26048 130 64472535
Decreased appetite 89.34 14.45 283 25784 281006 64191659
Injection site haematoma 87.39 14.45 39 26028 3897 64468768
Abdominal pain upper 82.08 14.45 203 25864 174827 64297838
Injection site pruritus 79.67 14.45 87 25980 37739 64434926
Blood glucose decreased 78.36 14.45 69 25998 23054 64449611
Pancreatitis necrotising 78.29 14.45 34 26033 3183 64469482
Dehydration 78.07 14.45 228 25839 216535 64256130
Toxicity to various agents 57.76 14.45 38 26029 363475 64109190
Pancreatic neoplasm 55.54 14.45 21 26046 1374 64471291
Neutropenia 54.00 14.45 15 26052 239609 64233056
Drug ineffective 53.22 14.45 169 25898 840078 63632587
Thyroid mass 53.20 14.45 26 26041 3191 64469474
Injection site reaction 51.66 14.45 78 25989 46586 64426079
Thyroid neoplasm 48.56 14.45 23 26044 2634 64470031
Pyrexia 47.15 14.45 97 25970 558547 63914118
Flatulence 45.86 14.45 64 26003 35602 64437063
Febrile neutropenia 45.66 14.45 10 26057 187647 64285018
Joint swelling 44.04 14.45 16 26051 215366 64257299
Pancreatic carcinoma stage IV 43.57 14.45 14 26053 563 64472102
Pancreatic pseudocyst 42.88 14.45 17 26050 1264 64471401
Dyspepsia 42.83 14.45 98 25969 80214 64392451
Completed suicide 42.10 14.45 19 26048 224395 64248270
Impaired gastric emptying 41.86 14.45 32 26035 8772 64463893
Weight loss poor 41.06 14.45 15 26052 891 64471774
Cholecystitis acute 40.70 14.45 35 26032 11325 64461340
Constipation 39.25 14.45 190 25877 229147 64243518
Cholangiocarcinoma 38.52 14.45 18 26049 2000 64470665
Hyperglycaemia 37.74 14.45 79 25988 60889 64411776
Haemoglobin decreased 37.39 14.45 16 26051 195047 64277618
Drug dose titration not performed 37.36 14.45 13 26054 670 64471995
Reversible cerebral vasoconstriction syndrome 35.97 14.45 18 26049 2324 64470341
Glycosylated haemoglobin decreased 34.76 14.45 12 26055 604 64472061
Infusion related reaction 33.98 14.45 12 26055 164455 64308210
Pancreatitis chronic 33.95 14.45 20 26047 3566 64469099
Treatment failure 33.37 14.45 4 26063 116812 64355853
Thyroid cancer 31.97 14.45 20 26047 3971 64468694
Death 31.92 14.45 95 25972 482610 63990055
White blood cell count decreased 31.79 14.45 12 26055 157825 64314840
Platelet count decreased 31.76 14.45 14 26053 167697 64304968
Anaemia 31.68 14.45 66 26001 378614 64094051
Abdominal distension 31.68 14.45 98 25969 95896 64376769
Pancreatic mass 31.64 14.45 14 26053 1370 64471295
Pneumonia 30.97 14.45 119 25948 559457 63913208
Thrombocytopenia 30.89 14.45 27 26040 223774 64248891
Leukopenia 30.11 14.45 3 26064 101239 64371426
Ketosis 29.66 14.45 12 26055 941 64471724
Gastrooesophageal reflux disease 29.42 14.45 87 25980 83056 64389609
Blood glucose abnormal 27.04 14.45 25 26042 8888 64463777
Pancreatic enzymes increased 26.98 14.45 12 26055 1189 64471476
Metastases to liver 26.46 14.45 40 26027 23901 64448764
Pain 25.56 14.45 126 25941 553385 63919280
Pancreatic cyst 25.13 14.45 13 26054 1799 64470866
Cholecystitis 24.89 14.45 35 26032 19601 64453064
Rheumatoid arthritis 23.67 14.45 19 26048 164275 64308390
Blood calcitonin increased 23.57 14.45 5 26062 36 64472629
Bile duct stone 23.46 14.45 18 26049 4960 64467705
Injection site hypersensitivity 23.15 14.45 12 26055 1667 64470998
Drug titration error 23.09 14.45 10 26057 930 64471735
Tonsillar ulcer 23.01 14.45 8 26059 411 64472254
Disease progression 22.20 14.45 15 26052 141665 64331000
Ductal adenocarcinoma of pancreas 21.44 14.45 6 26061 149 64472516
Goitre 21.31 14.45 17 26050 4956 64467709
Neutrophil count decreased 21.19 14.45 3 26064 77193 64395472
Drug intolerance 21.09 14.45 27 26040 187965 64284700
Glomerular filtration rate decreased 20.65 14.45 32 26035 19540 64453125
Bile acid malabsorption 20.52 14.45 6 26061 175 64472490
Malignant neoplasm progression 20.46 14.45 10 26057 112861 64359804
Product contamination with body fluid 20.44 14.45 3 26064 0 64472665
Contraindicated product administered 20.41 14.45 9 26058 107820 64364845
Pleural effusion 20.37 14.45 13 26054 126546 64346119
Injection site pain 20.26 14.45 94 25973 111314 64361351
Therapeutic product effect decreased 19.76 14.45 11 26056 115340 64357325
Thyroid cyst 19.66 14.45 7 26060 386 64472279
Obstructive pancreatitis 19.44 14.45 8 26059 655 64472010
Ludwig angina 19.25 14.45 6 26061 218 64472447
Hyperlipasaemia 19.25 14.45 9 26058 1001 64471664
Increased appetite 19.07 14.45 22 26045 10124 64462541
Palpitations 18.88 14.45 88 25979 104400 64368265
Breath odour 18.49 14.45 10 26057 1514 64471151
Aerococcus urinae infection 18.36 14.45 3 26064 3 64472662
Injection site nodule 18.19 14.45 13 26054 3217 64469448
Pancreatic neuroendocrine tumour 18.18 14.45 7 26060 481 64472184
Injection site irritation 18.15 14.45 13 26054 3227 64469438
Benign neoplasm of thyroid gland 17.99 14.45 8 26059 792 64471873
Arthralgia 17.99 14.45 105 25962 442155 64030510
Gastroenteritis 17.80 14.45 38 26029 29673 64442992
Arthropathy 17.41 14.45 14 26053 120953 64351712
Blood glucose fluctuation 16.72 14.45 16 26051 5939 64466726
Hepatic steatosis 16.70 14.45 38 26029 30969 64441696
Glossodynia 16.66 14.45 3 26064 64693 64407972
Blood ketone body increased 16.43 14.45 7 26060 625 64472040
Diabetic ketosis 16.41 14.45 6 26061 357 64472308
C-reactive protein increased 16.33 14.45 9 26058 94900 64377765
Device malfunction 16.10 14.45 27 26040 17606 64455059
Cholecystectomy 16.08 14.45 18 26049 8014 64464651
Gastrointestinal haemorrhage 15.90 14.45 18 26049 132294 64340371
Agitation 15.76 14.45 8 26059 88359 64384306
Nasopharyngitis 15.68 14.45 35 26032 196038 64276627
Diabetic neuropathy 15.63 14.45 15 26052 5586 64467079
Imminent abortion 15.62 14.45 3 26064 12 64472653
Dysgeusia 15.48 14.45 48 26019 46999 64425666
Product quality issue 15.48 14.45 36 26031 29763 64442902
Hypoglycaemic unconsciousness 15.42 14.45 8 26059 1113 64471552
Diabetic metabolic decompensation 15.41 14.45 11 26056 2717 64469948
Biliary colic 15.25 14.45 12 26055 3432 64469233
Pemphigus 15.24 14.45 3 26064 60698 64411967
Extrasystoles 15.22 14.45 16 26051 6642 64466023
Depressed level of consciousness 15.09 14.45 7 26060 81429 64391236
Urogenital infection fungal 15.07 14.45 3 26064 15 64472650
Supraventricular extrasystoles 14.94 14.45 15 26052 5900 64466765
Somnambulism 14.79 14.45 14 26053 5127 64467538
Pancytopenia 14.65 14.45 22 26045 143287 64329378
Electrocardiogram QT prolonged 14.46 14.45 7 26060 79441 64393224

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10AE56 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, long-acting
ATC A10BJ02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D054795 Incretins
FDA EPC N0000178480 GLP-1 Receptor Agonist
CHEBI has role CHEBI:63726 neuroprotective agents
CHEBI has role CHEBI:71196 GLP-1 receptor agonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Weight loss indication 89362005
Disorder of thyroid gland contraindication 14304000 DOID:50
Multiple endocrine neoplasia, type 2 contraindication 61808009
Pancreatitis contraindication 75694006 DOID:4989
C-cell hyperplasia of thyroid contraindication 237552009
Hypoglycemic disorder contraindication 237630007
Medullary thyroid carcinoma contraindication 255032005 DOID:3973
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.06 acidic
pKa2 3.31 acidic
pKa3 3.67 acidic
pKa4 3.82 acidic
pKa5 4.11 acidic
pKa6 4.44 acidic
pKa7 9.65 acidic
pKa8 11.84 acidic
pKa9 12.2 acidic
pKa10 12.53 acidic
pKa11 12.59 acidic
pKa12 12.81 acidic
pKa13 12.86 acidic
pKa14 12.94 acidic
pKa15 13.1 acidic
pKa16 13.15 acidic
pKa17 13.2 acidic
pKa18 13.29 acidic
pKa19 13.43 acidic
pKa20 13.56 acidic
pKa21 13.56 acidic
pKa22 13.6 acidic
pKa23 13.71 acidic
pKa24 13.82 acidic
pKa25 13.82 acidic
pKa26 13.96 acidic
pKa27 13.97 acidic
pKa28 11.05 Basic
pKa29 10.45 Basic
pKa30 7.87 Basic
pKa31 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
18MG/3ML (6MG/ML) VICTOZA NOVO NORDISK INC N022341 Jan. 25, 2010 RX SOLUTION SUBCUTANEOUS 6268343 Aug. 22, 2022 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
18MG/3ML (6MG/ML) SAXENDA NOVO N206321 Dec. 23, 2014 RX SOLUTION SUBCUTANEOUS 6268343 Aug. 22, 2022 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
18MG/3ML (6MG/ML) VICTOZA NOVO NORDISK INC N022341 Jan. 25, 2010 RX SOLUTION SUBCUTANEOUS 9968659 Jan. 9, 2037 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
18MG/3ML (6MG/ML) SAXENDA NOVO N206321 Dec. 23, 2014 RX SOLUTION SUBCUTANEOUS 9968659 Jan. 9, 2037 CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
18MG/3ML (6MG/ML) VICTOZA NOVO NORDISK INC N022341 Jan. 25, 2010 RX SOLUTION SUBCUTANEOUS June 17, 2022 NEW PATIENT POPULATION
18MG/3ML (6MG/ML) VICTOZA NOVO NORDISK INC N022341 Jan. 25, 2010 RX SOLUTION SUBCUTANEOUS Dec. 17, 2022 PEDIATRIC EXCLUSIVITY
18MG/3ML (6MG/ML) SAXENDA NOVO N206321 Dec. 23, 2014 RX SOLUTION SUBCUTANEOUS Dec. 4, 2023 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST EC50 10.20 WOMBAT-PK CHEMBL

External reference:

IDSource
D06404 KEGG_DRUG
4029703 VANDF
C1456408 UMLSCUI
CHEBI:71193 CHEBI
CHEMBL4524066 ChEMBL_ID
CHEMBL1201866 ChEMBL_ID
D000069450 MESH_DESCRIPTOR_UI
DB06655 DRUGBANK_ID
1133 IUPHAR_LIGAND_ID
8208 INN_ID
839I73S42A UNII
16134956 PUBCHEM_CID
1598264 RXNORM
166619 MMSL
232503 MMSL
26647 MMSL
d07466 MMSL
010773 NDDF
444828003 SNOMEDCT_US
444907006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 0169-2800 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 28 sections
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG LABEL 2 0169-2911 INJECTION, SOLUTION 3.60 mg SUBCUTANEOUS BLA 27 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 0169-4060 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 50090-2853 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 50090-4257 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 50090-4503 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections